Form 4: Teva Pharmaceutical CEO Richard Francis Granted Over 52,000 Restricted Share Units

Teva Pharmaceutical Industries Ltd.'s President and CEO, Richard D. Francis, was granted 52,173 Restricted Share Units (RSUs) on June 5, 2025, aligning his incentives with shareholder value.

Summary

• Richard D. Francis, President and CEO of Teva Pharmaceutical Industries Ltd. (TEVA), was granted 52,173 Restricted Share Units (RSUs).
• The transaction date for this grant was June 5, 2025.
• Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
• The RSUs will vest in four annual installments: 13,043 units on June 5, 2026, June 5, 2027, and June 5, 2028, and 13,044 units on June 5, 2029.

Sentiment

Score: 7

Explanation: The grant of RSUs to the CEO is a positive signal for long-term alignment of management interests with shareholders, a standard and generally well-regarded practice in corporate governance. It does not indicate any negative operational or financial news.

Positives

• The grant of Restricted Share Units to the President and CEO aligns management's long-term interests with those of shareholders, as the value of the units is tied to the company's stock performance.
• This form of equity compensation is a standard practice to incentivize executive retention and performance.

Negatives

• The issuance of new shares upon RSU vesting could lead to minor share dilution, although this is a common and expected aspect of equity compensation plans.

Risks

• The value of the Restricted Share Units is subject to the future performance of Teva Pharmaceutical Industries Ltd.'s ordinary shares, meaning the ultimate value realized by the CEO could be lower than the grant date value if the stock price declines.
• Potential for minor share dilution upon vesting of the RSUs, which is typical for equity compensation.

Future Outlook

The RSU grant indicates a long-term incentive structure for the CEO, aligning his future compensation with the company's performance and shareholder returns through 2029.

Industry Context

The grant of Restricted Share Units is a common practice in the pharmaceutical industry and across large corporations to attract, retain, and incentivize top executive talent. This form of compensation ties executive rewards directly to the long-term performance of the company's stock, which is a standard approach to corporate governance.

Comparison to Industry Standards

• The use of Restricted Share Units (RSUs) as a form of executive compensation is a widely adopted practice across global industries, including major pharmaceutical companies like Pfizer, Johnson & Johnson, and Novartis, which frequently utilize similar equity-based incentives to align executive interests with long-term shareholder value.
• The multi-year vesting schedule (four years) for these RSUs is consistent with typical industry benchmarks for executive equity grants, designed to promote long-term commitment and performance rather than short-term gains.
• The specific number of units granted would typically be evaluated in the context of the CEO's overall compensation package, company size, and performance metrics, but the mechanism itself is standard.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting of RSUs, but also increased alignment of CEO's interests with long-term shareholder value creation.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation philosophy.
• Management: Provides a significant long-term incentive for the CEO, tying a portion of his compensation directly to the company's stock performance.

Next Steps

• Vesting of 13,043 Restricted Share Units on June 5, 2026.
• Vesting of 13,043 Restricted Share Units on June 5, 2027.
• Vesting of 13,043 Restricted Share Units on June 5, 2028.
• Vesting of 13,044 Restricted Share Units on June 5, 2029.

Key Dates

Keywords

Teva Pharmaceutical, TEVA, Richard D. Francis, Restricted Share Units, RSU, Executive Compensation, Insider Transaction, SEC Form 4, Equity Grant, Pharmaceutical Industry